Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study

H. Kerstjens (Groningen, Netherlands), R. Van Zyl-Smit (Cape Town, South Africa), K. Chapman (Toronto, Canada), J. Maspero (Buenos Aires, Argentina), M. Hosoe (Basel, Switzerland), A. Tanase (Basel, Switzerland), D. Lawrence (Basel, Switzerland), A. Pethe (NJ, United States of America), X. Shu (NJ, United States of America), K. Mezzi (Basel, Switzerland), P. D'Andrea (NJ, United States of America)

Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence

Session: Asthma inhalers: new devices and adherence
Session type: E-poster
Number: 3387

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Kerstjens (Groningen, Netherlands), R. Van Zyl-Smit (Cape Town, South Africa), K. Chapman (Toronto, Canada), J. Maspero (Buenos Aires, Argentina), M. Hosoe (Basel, Switzerland), A. Tanase (Basel, Switzerland), D. Lawrence (Basel, Switzerland), A. Pethe (NJ, United States of America), X. Shu (NJ, United States of America), K. Mezzi (Basel, Switzerland), P. D'Andrea (NJ, United States of America). Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study. 3387

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Mometasone/indacaterol (MF/IND) and mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) and FLU/SAL+tiotropium (TIO) in patients with inadequately controlled asthma: data from the PLATINUM program Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017
Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials Source: ERJ Open Res, 7 (1) 00816-2020; 10.1183/23120541.00816-2020 Year: 2021
Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials Source: International Congress 2018 – COPD management Year: 2018
Treatment response in COPD: does FEV₁ say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019
Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial Source: International Congress 2018 – Primary care management of respiratory conditions Year: 2018
The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma Source: ERJ Open Res, 7 (4) 00271-2021; 10.1183/23120541.00271-2021 Year: 2021
Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017
LATE-BREAKING ABSTRACT: Association of incident pneumonia and exacerbations with extrafine beclometasone dipropionate/formoterol (BDP/FF) in severe COPD patients: A post-hoc analysis of FORWARD study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002